Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-05-03
1998-12-15
Gupta, Yogendra N.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514252, 514255, 514256, 514307, 514311, 514332, 514337, 514339, 514340, 514341, 514342, 544238, 544333, 544405, 546148, 546174, 546255, 5462684, 546309, A61K 3144, A61K 31505, C07D21372, C07D23926
Patent
active
058497692
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to compounds and pharmaceutically acceptable salts thereof and methods for treating infections by HIV and related viruses and/or the treatment of Acquired Immune Deficiency Syndrome (AIDS). Also disclosed are pharmaceutical compositions containing the compounds and the method of use of the present compounds alone or in combination with other agents, for the treatment and inhibition of AIDS and viral infection from HIV.
BACKGROUND OF THE INVENTION
A retrovirus designated Human Immunodeficiency Virus (HIV) is believed to be the causative agent of the complex disease termed Acquired Immune Deficiency Syndrome (AIDS) and is a member of the lentivirus family of retroviruses (M. A. Gonda, F. Wong-Staal NR. C. Gallo, "Sequence Homology and Morphological Similarity of HTLV III and Visna Virus, A Pathogenic Lentivirus", Science, 227, 173, (1985); and P. Sonigo and N. Alizon, et al., "Nucleotide Sequence of the Visna Lentivirus: Relationship to the AIDS Virus", Cell, 42, 369, (1985)). The HIV virus (also referred to as the AIDS virus) was previously known as or referred to as LAV, HTLV-III, or ARV, and is now designated by HIV-1. Other closely related variants of HIV-1 include HIV-2 and SIV (simian immunodeficiency virus), and mutants thereof. The complex disease AIDS includes progressive destruction of the immune system and degeneration of the central and peripheral nervous system. The HIV virus appears to preferentially attack helper T-cells (T-lymphocytes or OKT4-bearing T-cells) and also other human cells, e.g., certain cells within the brain. The helper T-cells are invaded by the virus and the T-cell becomes an HIV virus producer. The helper T-cells are quickly destroyed and their number in the human being is depleted to such an extent that the body's B-cells as well as other T-cells normally stimulated by helper T-cells no longer function normally or produce sufficient lymphokines and antibodies to destroy the invading virus or other invading microbes.
While the HIV virus does not necessarily cause death per se, it does cause the human's immune system to be so severely depressed that the human falls prey to various other diseases such as herpes, Pneumocystis carinii, toxoplasmosis, cytomegalovirus, Kaposi's sarcoma, and Epstein-Barr virus related lymphomas among others. These secondary infections are separately treated using other medications as is conventional. Early during infection, humans with HIV virus seem to live on with little or no symptoms, but have persistent infections. Later in the disease, humans suffer mild immune system depression with various symptoms such as weight loss, malaise, fever, and swollen lymph nodes. These syndromes have been called persistent generalized lymphadenopathy syndrome (PGL) and AIDS related complex (ARC) and develop into AIDS.
In all cases, those infected with the AIDS virus are believed to be persistently infective to others. Further, AIDS and AIDS related complex is after some time fatal.
A description of the mechanism by which the virus infects its host is given in an article by R. Yarchoan, and S. Broder, "Development of Antiretroviral Therapy for the Acquired Immunodeficiency Syndrome and Related Disorders", New England Journal of Medicine, 316, 557-564 (Feb. 26, 1987).
Considerable efforts are being directed toward the control of HIV by means of inhibition of the reverse transcriptase of HIV, required for replication of the virus. (V. Merluzzi et al., "Inhibition of the HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor", Science, 25, 1411 (1990)). For example, a currently used therapeutic compound, AZT, is an inhibitor of the viral reverse transcriptase (U.S. Pat. No. 4,724,232). Unfortunately, many of the now used compounds suffer from toxicity problems, lack of bioavailability or are short lived in vivo, viral resistance, or combinations thereof. Therefore, new compounds are being investigated. For example, a PCT application published on Feb. 18, 1993, (WO 93/03022; International Applica
REFERENCES:
patent: 5308866 (1994-05-01), Lesieur et al.
patent: 5380750 (1995-01-01), Lesieur et al.
patent: 5385944 (1995-01-01), Lesieur et al.
patent: 5389683 (1995-02-01), Lesieur et al.
patent: 5420158 (1995-05-01), Yous et al.
H. Willitzer et al., Pharmazie 33, H. 1 (1978), pp. 30-38.
V.P. Arya et al., Synthesis of Adamantane Derivatives with Potential Antiviral Activity, Indian Journal of Chemistry, Vol. 10 (Jul. 1992), pp. 686-689.
Chemical Abstracts 116:235102, 1992.
Chemical Abstracts 113:23837, 1989.
Chemical Abstracts 109:106992, 1988.
Chemical Abstracts 108:94583, 1987.
Chemical Abstracts 100:29502, 1983.
Chemical Abstracts 98:143211, 1983.
Chemical Abstracts 95:203851, 1981.
Chemical Abstracts 93:234301, 1980.
Chemical Abstracts 92:70288, 1979.
Chemical Abstracts 91:82986, 1979.
Chemical Abstracts 91:50948, 1979.
Chemical Abstracts 88:37969, 1977.
Chemical Abstracts 87:177464, 1977.
Chemical Abstracts 87:17148, 1977.
Chemical Abstracts 82:72917, 1974.
Chemical Abstracts 79:126522, 1973.
Chemical Abstracts 78:119098, 1973.
Lind Peter Thomas
Morin John Michael
Noreen Rolf
Ternansky Robert John
Gupta Yogendra N.
Medivir AB
LandOfFree
N-arylalkyl-N-heteroarylurea and guandine compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-arylalkyl-N-heteroarylurea and guandine compounds and methods , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-arylalkyl-N-heteroarylurea and guandine compounds and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1458355